3.9 Article

Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells

Journal

BMC DEVELOPMENTAL BIOLOGY
Volume 9, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-213X-9-12

Keywords

-

Funding

  1. American Society of Clinical Oncology (ASCO)
  2. Spanish Ministry of Health [G03/089, FIS 2004/PI041259]
  3. Catalan government [2005SGR00605]

Ask authors/readers for more resources

Background: Neuroblastic tumors (NBT) derive from neural crest stem cells (NCSC). Histologically, NBT are composed by neuroblasts and Schwannian cells. In culture, neuroblastic (N), substrate-adherent (S-) and intermediate phenotype (I-) cell subtypes arise spontaneously. Methods: Here, neuroblastoma (NB) cell line subtypes were characterized according to embryonic peripheral nervous system development markers (GAP43, Phox2b, Sox10, c-kit, GD2, NF68, vimentin, S100 beta, calcyclin and ABCG2), morphological features, gene expression and differentiation potential. I-type cells were investigated as a bipotential (neuronal and glial) differentiation stage. Results: Positive immunostaining of NCSC (GAP43, c-kit, NF68, vimentin and Phox2b) and undifferentiated cell (ABCG2) markers was observed in all NB subtypes. N- and I-type cells displayed cytoplasmic membrane GD2 staining, while nuclear calcyclin was restricted to S-type. Nand I-type cells showed similar phenotype and immunoreactivity pattern. Differential gene expression was associated with each cell subtype. N- and I-type cells displayed similar differentiation capacity towards neuronal and glial lineage fates. S-type cells, upon induction, did not show a neuronal-like phenotype, despite gene expression changes. Conclusion: Results suggest that N- and I-type NB cell subtypes represent an immature bilineage stage, able to progress towards neuronal and glial fates upon induction of differentiation. S-type cells appear irreversibly committed to a glial lineage fate.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Developmental Biology

Use of two gRNAs for CRISPR/Cas9 improves bi-allelic homologous recombination efficiency in mouse embryonic stem cells

Sandra Acosta, Luciano Fiore, Isabel Anna Carota, Guillermo Oliver

GENESIS (2018)

Article Cell Biology

Human Pluripotent Stem-Cell-Derived Cortical Neurons Integrate Functionally into the Lesioned Adult Murine Visual Cortex in an Area-Specific Way

Ira Espuny-Camacho, Kimmo A. Michelsen, Daniele Linaro, Angeline Bilheu, Sandra Acosta-Verdugo, Adele Herpoel, Michele Giugliano, Afsaneh Gaillard, Pierre Vanderhaeghen

CELL REPORTS (2018)

Article Developmental Biology

Optic vesicle morphogenesis requires primary cilia

Luciano Fiore, Nozomu Takata, Sandra Acosta, Wanshu Ma, Tanushree Pandit, Michael Oxendine, Guillermo Oliver

DEVELOPMENTAL BIOLOGY (2020)

Article Multidisciplinary Sciences

Adaptive selection drives TRPP3 loss-of-function in an Ethiopian population

Sandra Walsh, Merce Izquierdo-Serra, Sandra Acosta, Albert Edo, Maria Lloret, Roser Moret, Elena Bosch, Baldo Oliva, Jaume Bertranpetit, Jose Manuel Fernandez-Fernandez

SCIENTIFIC REPORTS (2020)

Article Oncology

Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations

Brigitte Royer-Pokora, Maike Anna Busch, Sarah Tenbusch, Mathias Schmidt, Manfred Beier, Andrew D. Woods, Holger Thiele, Jaume Mora

Summary: Wilms tumors are childhood kidney tumors that are heterogeneous with distinct subgroups, including a subtype associated with WT1 gene mutations. Researchers have successfully established 11 cell lines from the WT1 mutant subtype, providing a valuable tool for studying the biology and genetics of this specific type of Wilms tumor. These cell lines may lead to new approaches in treatment development.

CANCERS (2021)

Article Biochemistry & Molecular Biology

Enhancers with tissue-specific activity are enriched in intronic regions

Beatrice Borsari, Pablo Villegas-Miron, Silvia Perez-Lluch, Isabel Turpin, Hafid Laayouni, Alba Segarra-Casas, Jaume Bertranpetit, Roderic Guigo, Sandra Acosta

Summary: The study explored the correlation between the genomic location of active enhancers and tissue-specific gene expression, revealing that tissue-specific enhancers are enriched in intronic regions and control genes involved in tissue-specific functions. The results suggest that the genomic location of active enhancers is crucial for the tissue-specific control of gene expression, with the transition from developmental to adult stages showing a continuum of intergenic to intronic enhancers.

GENOME RESEARCH (2021)

Article Biochemistry & Molecular Biology

Comparative Analysis of Mammal Genomes Unveils Key Genomic Variability for Human Life Span

Xavier Farre, Ruben Molina, Fabio Barteri, Paul R. H. J. Timmers, Peter K. Joshi, Baldomero Oliva, Sandra Acosta, Borja Esteve-Altava, Arcadi Navarro, Gerard Muntane

Summary: The study identified amino acid changes and genes related to longevity in mammals, with pathways involved in regulating lifespan. It also found that certain genes explain a larger fraction of human lifespan heritability than expected, with longevity-associated proteins being significantly more stable. Overall, the research demonstrates the potential of comparative genomics in enhancing understanding of human genome-wide association studies.

MOLECULAR BIOLOGY AND EVOLUTION (2021)

Article Genetics & Heredity

Chromosome X-wide Analysis of Positive Selection in Human Populations: Common and Private Signals of Selection and its Impact on Inactivated Genes and Enhancers

Pablo Villegas-Miron, Sandra Acosta, Jessica Nye, Jaume Bertranpetit, Hafid Laayouni

Summary: Recent positive selection events on the X chromosome in human populations show a higher number among sub-Saharan Africans compared to non-African populations. A global enrichment of neural-related processes and the importance of fertility-related genes in human evolution are observed. Commonalities in genes across different continental groups, as well as signals in genes that escape X chromosome inactivation, are reported.

FRONTIERS IN GENETICS (2021)

Review Oncology

Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review

Jaume Mora

Summary: This article reviews the history of high-dose chemotherapy in the field of oncology and finds that it has not shown significant benefits in the treatment of solid tumors in adults, except for high-risk neuroblastoma. However, new immunotherapy approaches have demonstrated significant survival benefits with lesser side effects.

CANCERS (2022)

Review Oncology

Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies

Sara Sanchez-Molina, Elisabet Figuerola-Bou, Victor Sanchez-Margalet, Luis de la Cruz-merino, Jaume Mora, Enrique de alava Casado, Daniel Jose Garcia-Dominguez, Lourdes Hontecillas-Prieto

Summary: Ewing Sarcoma treatment traditionally involves chemotherapy, surgery, and radiotherapy, but many patients do not respond well, prompting the search for more effective treatments. Recent advancements in epigenetic and immunotherapy-based drugs, as well as nanotechnology delivery systems, offer promising alternatives for improving the therapeutic response in Ewing Sarcoma patients. Research in the last decade has focused on targeting epigenetic dependencies and the immune system, as well as utilizing nanomedicine for more effective drug delivery to address challenges associated with standard therapies in Ewing Sarcoma.

CANCERS (2022)

Review Cell Biology

Understanding the neurological implications of acute and long COVID using brain organoids

Laura Garcia-Gonzalez, Andrea Marti-Sarrias, Maria C. Puertas, Angel Bayon-Gil, Patricia Resa-Infante, Javier Martinez-Picado, Arcadi Navarro, Sandra Acosta

Summary: The acute phase of COVID-19 may have long-term implications, leading to chronic disorders that can last for months or even years. Neurological manifestations can vary in severity and may persist for more than 12 weeks after the initial infection. Brain organoid models provide valuable insights into the neuropathology of acute and long COVID, allowing for a better understanding of the underlying mechanisms.

DISEASE MODELS & MECHANISMS (2023)

Article Oncology

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

Juan Pablo Munoz, Cristina Larrosa, Saray Chamorro, Sara Perez-Jaume, Margarida Simao, Nazaret Sanchez-Sierra, Amalia Varo, Maite Gorostegui, Alicia Castaneda, Moira Garraus, Sandra Lopez-Miralles, Jaume Mora

Summary: This study investigated the effectiveness of naxitamab-based chemo-immunotherapy in treating primary chemo-resistant high-risk neuroblastoma. The results showed that early treatment with naxitamab-based therapy significantly improved the survival rate of patients, indicating it as an effective treatment option.

CANCERS (2023)

Review Oncology

GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma

Jaume Mora, Shakeel Modak, Joyce Kinsey, Carolyn E. Ragsdale, Hillard M. Lazarus

Summary: Colony-stimulating factors, such as GM-CSF, have been studied extensively for their potential to enhance the effectiveness of anti-GD2 monoclonal antibodies in high-risk neuroblastoma. However, access to these therapies is not uniform, and there is limited clinical data supporting the use of G-CSF as an alternative to GM-CSF. More research is needed to ensure equitable access to these treatments globally.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events

Jaume Mora, Godfrey C. Chan, Daniel A. Morgenstern, Karsten Nysom, Melissa K. Bear, Karen Tornoe, Brian H. Kushner

Summary: This article reviews the safety profile and adverse event management of naxitamab in a pediatric population, providing protocol-based recommendations for AE management and emphasizing the importance of close monitoring and timely intervention to ensure maximum clinical benefit from naxitamab therapy.

CANCER REPORTS (2023)

Article Oncology

Treatment of childhood astrocytomas with irinotecan and cisplatin

J. Mora, S. Perez-Jaume, O. Cruz

CLINICAL & TRANSLATIONAL ONCOLOGY (2018)

No Data Available